Type 3 Autoimmune Pancreatitis: What Do We Know So Far?
Review
OA: gold
CC-BY-NC-4.0
Abstract
The increasing use of immune checkpoint inhibitors (ICIs) in cancer treatment has led to a rise in immune-related adverse events (irAEs). Type 3 autoimmune pancreatitis (AIP-3) has been proposed as a rare form of pancreatic injury induced by ICIs with autoimmune pancreatitis-like features and variable presentations. Its diagnosis is not straightforward. Moreover, the role of available therapeutic options, particularly mainly glucocorticosteroids (GCS), remains uncertain. Currently, there are no clear guidelines for AIP-3 management. Data on AIP-3 are derived mainly from small retrospective studies and provide limited-quality evidence. In addition, the diagnostic criteria and management of AIP-3 vary substantially between studies. Some researchers have classified asymptomatic pancreatic enzyme elevations during ICI therapy as AIP-3; however, isolated hyperlipasemia should not be considered sufficient for this diagnosis. This comprehensive, narrative review summarizes current knowledge about AIP-3 and discusses epidemiology, etiopathogenesis, clinical presentations, diagnosis, and treatment based on the most recent evidence.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
SciLite annotations
chemicals 17
steroid
corticosteroid
prednisone
prednisolone
prednisone
prednisolone
etanercept
prednisolone
azathioprine
mycophenolate mofetil
steroid
alcohol
pembrolizumab
pembrolizumab
alcohol
gadolinium
corticosteroid
organisms 1
men 2004071
Source provenance
- europepmc
- last seen: 2026-11-15T09:34:25.365398+00:00
- scilite
- last seen: 2026-11-15T10:16:09.319260+00:00
- unpaywall
- last seen: 2026-11-16T06:37:28.113292+00:00
License: CC-BY-NC-4.0